Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning
- PMID: 28569345
- DOI: 10.1007/s10103-017-2241-7
Vascular targeted photodynamic therapy with TOOKAD® Soluble (WST11) in localized prostate cancer: efficiency of automatic pre-treatment planning
Abstract
Vascular targeted photodynamic therapy (VTP) with WST11 is a novel non-thermal focal treatment for localized prostate cancer that has shown favorable and early efficacy results in previously published studies. In this work, we investigate the efficiency of automatic dosimetric treatment planning. An action model established in a previous study was used in an image-guided optimization scheme to define the personalized optimal light dose for each patient. The calculated light dose is expressed as the number of optical cylindrical fibers to be used, their positions according to an external insertion grid, and the lengths of their diffuser parts. Evaluation of the method was carried out on data collected from 17 patients enrolled in two multi-centric clinical trials. The protocol consisted of comparing the method-simulated necrosis to the result observed on day 7 MR enhanced images. The method performances showed that the final result can be estimated with an accuracy of 10%, corresponding to a margin of 3 mm. In addition, this process was compatible with clinical conditions in terms of calculation times. The overall process took less than 10 min. Different aspects of the VTP procedure were already defined and optimized. Personalized treatment planning definition remained as an issue needing further investigation. The method proposed herein completes the standardization of VTP and opens new pathways for the clinical development of the technique.
Keywords: Image guided procedure; Photodynamic therapy; Prostate cancer; Treatment planning.
Similar articles
-
TOOKAD(®) Soluble vascular-targeted photodynamic (VTP) therapy: determination of optimal treatment conditions and assessment of effects in patients with localised prostate cancer.BJU Int. 2013 Oct;112(6):766-74. doi: 10.1111/bju.12265. BJU Int. 2013. PMID: 24028764 Clinical Trial.
-
Determination of optimal drug dose and light dose index to achieve minimally invasive focal ablation of localised prostate cancer using WST11-vascular-targeted photodynamic (VTP) therapy.BJU Int. 2015 Dec;116(6):888-96. doi: 10.1111/bju.12816. Epub 2015 Apr 21. BJU Int. 2015. PMID: 24841929 Clinical Trial.
-
Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.World J Urol. 2015 Jul;33(7):937-44. doi: 10.1007/s00345-015-1535-2. Epub 2015 Mar 19. World J Urol. 2015. PMID: 25786708 Free PMC article.
-
Treatment of localized prostate cancer using WST-09 and WST-11 mediated vascular targeted photodynamic therapy-A review.Photodiagnosis Photodyn Ther. 2015 Dec;12(4):567-74. doi: 10.1016/j.pdpdt.2015.10.001. Epub 2015 Oct 20. Photodiagnosis Photodyn Ther. 2015. PMID: 26467273 Review.
-
[Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review].Prog Urol. 2019 Jul-Aug;29(8-9):393-401. doi: 10.1016/j.purol.2019.05.004. Epub 2019 Jun 29. Prog Urol. 2019. PMID: 31266699 Review. French.
Cited by
-
Clinical development of photodynamic agents and therapeutic applications.Biomater Res. 2018 Sep 26;22:25. doi: 10.1186/s40824-018-0140-z. eCollection 2018. Biomater Res. 2018. PMID: 30275968 Free PMC article. Review.
-
Porphyrin Macrocycles: General Properties and Theranostic Potential.Molecules. 2023 Jan 23;28(3):1149. doi: 10.3390/molecules28031149. Molecules. 2023. PMID: 36770816 Free PMC article. Review.
-
Automatic interstitial photodynamic therapy planning via convex optimization.Biomed Opt Express. 2018 Jan 30;9(2):898-920. doi: 10.1364/BOE.9.000898. eCollection 2018 Feb 1. Biomed Opt Express. 2018. PMID: 29552420 Free PMC article.
-
Feasibility of antimicrobial photodynamic therapy for treatment of breast abscesses: Retrospective Monte Carlo simulation study.Photochem Photobiol. 2025 Mar 4:10.1111/php.14085. doi: 10.1111/php.14085. Online ahead of print. Photochem Photobiol. 2025. PMID: 40038906
-
Photodynamic therapy for prostate cancer: Recent advances, challenges and opportunities.Front Oncol. 2022 Sep 23;12:980239. doi: 10.3389/fonc.2022.980239. eCollection 2022. Front Oncol. 2022. PMID: 36212416 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical